SCHEMBL8337902

SCHEMBL8337902

Cc1ccc(-n2ccncc2=O)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2E1 P05181 2/20 0.49
ELANE P08246 2/20 0.44
MAPK14 Q16539 1/20 0.40
PTGS2 P35354 1/20 0.37
ALDH1A1 P00352 2/20 0.36
EP300 Q09472 1/20 0.36
KAT2B Q92831 1/20 0.36
APP P05067 1/20 0.35
HTT P42858 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
CYP19A1 P11511 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
DRD3 P35462 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14490257 0.82 CYP2A6 (0.43) CYP2A6CYP3A4CYP2E1MAPK14ALDH1A1
SCHEMBL8266914 0.80 F2 (0.42) CYP2A6CYP3A4CYP2E1ELANEMAPK14
SCHEMBL14525383 0.79 CYP2A6 (0.41) CYP2A6CYP3A4CYP2E1ELANEMAPK14
SCHEMBL27253970 0.78 ELANE (0.43) CYP2A6CYP3A4CYP2E1ELANEPTGS2
SCHEMBL1044182 0.77 ELANE (0.45) CYP2A6CYP3A4CYP2E1ELANEALDH1A1
SCHEMBL14525390 0.76 CYP3A4 (0.38) CYP2A6CYP3A4CYP2E1MAPK14F10
SCHEMBL8285971 0.75 ELANE (0.46) CYP2A6CYP3A4CYP2E1ELANEPTGS2
SCHEMBL29683214 0.74 BCHE (0.43) CYP2A6CYP3A4CYP2E1MAPK14ALDH1A1
SCHEMBL77918 0.73 MAPT (0.48) MAPK14ALDH1A1HTTCYP19A1F10
SCHEMBL27250688 0.72 KDM4E (0.56) CYP2A6CYP2E1ELANEMAPK14PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070129361-A1 LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-07 US disclosed
US-20070129361-A1 LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-07 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 US disclosed
WO-2004031145-A2 LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD CYP2A6 2113/4885CYP3A4 1311/4885CYP2E1 4078/4885
US-20070129361-A1 LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS PEPD, XPNPEP1, METAP1 CYP2A6 2139/4885CYP3A4 2461/4885CYP2E1 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.